JACC. Heart failure最新文献

{"title":"Outcome and Disease Progression in NYHA Functional Class I and II Patients With Wild-Type Transthyretin Cardiomyopathy Treated With Tafamidis","authors":"Giulio Sinigiani MD , Giuseppe Damiano Sanna MD, PhD , Alberto Aimo MD, PhD , Aldostefano Porcari MD , Giacomo Bonacchi MD , Laura De Michieli MD, PhD , Paolo Milani MD, PhD , Giuseppe Vergaro MD, PhD , Giacomo Tini MD, PhD , Marco Baldan MD , Paola Martire MD , Alberto Beghini MD , Daniela Tomasoni MD , Giuseppe Palmiero MD , Paolo Ossola MD , Francesco Musca MD , Mattia Zampieri MD, PhD , Gabriele Guidi Colombi MD , Matteo Serenelli MD, PhD , Roberto Cemin MD , Alberto Cipriani MD","doi":"10.1016/j.jchf.2025.102549","DOIUrl":"10.1016/j.jchf.2025.102549","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 8","pages":"Article 102549"},"PeriodicalIF":10.3,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144535213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Seeing Is Believing","authors":"Imo A. Ebong MD, MS , Ravi B. Patel MD, MS","doi":"10.1016/j.jchf.2025.102532","DOIUrl":"10.1016/j.jchf.2025.102532","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 8","pages":"Article 102532"},"PeriodicalIF":10.3,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144522033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"When the Data Changes, So Should We","authors":"Scott C. Silvestry MD","doi":"10.1016/j.jchf.2025.04.009","DOIUrl":"10.1016/j.jchf.2025.04.009","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 7","pages":"Article 102494"},"PeriodicalIF":10.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Current Landscape of Training, Practice, and Roles of Pharmacists in the Field of Heart Failure","authors":"Mona Fiuzat PharmD , Bassam Atallah PharmD , Robert Page PharmD , Orly Vardeny PharmD","doi":"10.1016/j.jchf.2025.102551","DOIUrl":"10.1016/j.jchf.2025.102551","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 8","pages":"Article 102551"},"PeriodicalIF":10.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144517512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Initiating Medical Therapy in Cardiogenic Shock Patients on Temporary Mechanical Circulatory Support","authors":"Joshua Genstler MD, Robin Miller DNP, Shih Ting Chiu PhD, Kateri J. Spinelli PhD, Jacob Abraham MD","doi":"10.1016/j.jchf.2025.102534","DOIUrl":"10.1016/j.jchf.2025.102534","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 8","pages":"Article 102534"},"PeriodicalIF":10.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144517511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stroke in Heart Failure With Reduced Ejection Fraction","authors":"Guglielmo Gallone MD ,&nbsp;Federica Savoca MD ,&nbsp;Davide Miccoli MD ,&nbsp;Michael Böhm MD, PhD ,&nbsp;Gaetano Maria De Ferrari MD ,&nbsp;Stephen S. Gottlieb MD ,&nbsp;Patrizio Lancellotti MD, PhD ,&nbsp;JoAnn Lindenfeld MD ,&nbsp;Clara Saldarriaga MD ,&nbsp;Zainab Samad MBBS ,&nbsp;John R. Teerlink MD ,&nbsp;Gianluigi Savarese MD, PhD ,&nbsp;Enrico Ammirati MD, PhD","doi":"10.1016/j.jchf.2024.12.008","DOIUrl":"10.1016/j.jchf.2024.12.008","url":null,"abstract":"<div><h3>Background</h3><div>Patients with heart failure with reduced ejection fraction (HFrEF) have a heightened stroke risk. However, stroke as an endpoint in heart failure trials remains under-reported.</div></div><div><h3>Objectives</h3><div>The authors sought to define the incidence, characteristics, predictors, modifier treatments, and prognostic impact of stroke in patients with HFrEF who were enrolled in randomized controlled trials (RCTs).</div></div><div><h3>Methods</h3><div>The authors systematically reviewed MEDLINE for RCTs of pharmacologic and nonpharmacologic treatments in HFrEF. The annualized stroke incidence was the primary outcome. Subgroup analyses and meta-regressions were performed to determine the baseline modulating characteristics and to assess the association of stroke with other clinical outcomes.</div></div><div><h3>Results</h3><div>Of 7,104 records, 188 RCTs fulfilled inclusion criteria for the systematic review. Of these, 158 studies (84.0%) did not report stroke outcomes and were excluded from the meta-analysis, leading to a final cohort of 30 studies, with 61 arms and 75,327 patients. Stroke incidence was 1.1% (95% CI: 0.9%-1.3%; I²: 74%) with high heterogeneity across trials. Higher NYHA functional class (<em>P &lt;</em> 0.001), lower systolic blood pressure (<em>P &lt;</em> 0.001), diuretic use (<em>P =</em> 0.001), and diabetes (<em>P &lt;</em> 0.001) were associated with stroke. No association of renin-angiotensin-aldosterone inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and transcatheter mitral valve replacement with stroke was observed. Stroke was associated with higher risk of all-cause and cardiovascular mortality, heart failure hospitalization and acute coronary syndromes (<em>P &lt;</em> 0.001 for all).</div></div><div><h3>Conclusions</h3><div>Stroke was reported in a vast minority of HFrEF RCTs with heterogeneous definitions and no reference to underlying mechanisms. Despite under-reporting, stroke incidence is non-negligible. Stroke is associated with HFrEF-specific characteristics and outcomes, whereas it is not impacted by current HFrEF treatments. There is a need for dedicated research into preventive strategies and effective treatments to address this debilitating and deadly comorbidity. (Stroke Events in Heart Failure With Reduced Ejection Fraction–A Systematic Review and Meta-Analysis of Pharmacologic Randomized Trial; <span><span>CRD42023418422</span><svg><path></path></svg></span>)</div></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 7","pages":"Article 102389"},"PeriodicalIF":10.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Full issue PDF","authors":"","doi":"10.1016/S2213-1779(25)00463-9","DOIUrl":"10.1016/S2213-1779(25)00463-9","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 7","pages":"Article 102536"},"PeriodicalIF":10.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144570763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interleukin-6 in Heart Failure With Reduced Ejection Fraction and the Effect of Dapagliflozin","authors":"Kieran F. Docherty MBChB, PhD ,&nbsp;Kirsty McDowell MBChB ,&nbsp;Paul Welsh PhD ,&nbsp;Mark C. Petrie MBChB ,&nbsp;Inder Anand MD, PhD ,&nbsp;David D. Berg MD, MPH ,&nbsp;Rudolf A. de Boer MD, PhD ,&nbsp;Lars Køber MD, DMSc ,&nbsp;Mikhail N. Kosiborod MD ,&nbsp;Felipe A. Martinez MD ,&nbsp;Eileen O’Meara MD ,&nbsp;David A. Morrow MD, MPH ,&nbsp;Piotr Ponikowski MD, PhD ,&nbsp;Marc S. Sabatine MD, MPH ,&nbsp;Naveed Sattar MBChB, PhD ,&nbsp;Morten Schou MD, PhD ,&nbsp;Ann Hammarstedt PhD ,&nbsp;Mikaela Sjöstrand MD, PhD ,&nbsp;Anna Maria Langkilde MD, PhD ,&nbsp;Pardeep S. Jhund MBChB, PhD ,&nbsp;John J.V. McMurray MD","doi":"10.1016/j.jchf.2024.12.012","DOIUrl":"10.1016/j.jchf.2024.12.012","url":null,"abstract":"<div><h3>Background</h3><div>Inflammation may play an important pathophysiological role in the development and progression of heart failure (HF). Interleukin (IL)-6 is a circulating cytokine and is the main regulator of the release of C-reactive protein (CRP).</div></div><div><h3>Objectives</h3><div>The authors examined the association between IL-6 and high-sensitivity (hs)-CRP and outcomes in patients with HFrEF in the DAPA-HF trial and their relationship with the effect of dapagliflozin.</div></div><div><h3>Methods</h3><div>Inclusion criteria included: 1) NYHA functional class II-IV; 2) left ventricular ejection fraction ≤40%; 3) elevated N-terminal pro–B-type natriuretic peptide; and 4) estimated glomerular filtration rate ≥30 mL/min/1.73 m². The primary outcome was a composite of a worsening HF event or cardiovascular death. IL-6 and hs-CRP were measured at baseline and 12 months (Roche Diagnostics). The associations between IL-6 and hs-CRP and outcomes were adjusted for known prognostic variables, including NT-proBNP.</div></div><div><h3>Results</h3><div>Among 2,940 patients, median IL-6 and hs-CRP at baseline were 6.01 pg/mL (Q1-Q3: 4.18-9.28 pg/mL) and 2.05 mg/L (Q1-Q3: 0.83-4.9 mg/L), respectively. Baseline IL-6 tertiles (T) were: T1 ≤4.72 pg/mL; T2 4.73-7.89 pg/mL; and T3 ≥7.90 pg/mL. The adjusted risks of the primary outcome relative to T1 were as follows: T2 = HR 1.34 (95% CI: 1.04-1.73) and T3 = HR 1.80 (95% CI: 1.41-2.31). A rise in IL-6 between baseline and 12 months was associated with worse outcomes. The beneficial effect of dapagliflozin on the primary outcome was consistent regardless of IL-6 concentration (continuous interaction <em>P =</em> 0.57), with similar results for hs-CRP. Dapagliflozin did not reduce IL-6 or hs-CRP at 12 months.</div></div><div><h3>Conclusions</h3><div>In DAPA-HF, elevated IL-6 and hs-CRP levels were each associated with the risk of worsening HF or cardiovascular death. Dapagliflozin reduced the risk of adverse outcomes regardless of baseline IL-6 or hs-CRP. (Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure [DAPA-HF]; <span><span>NCT03036124</span><svg><path></path></svg></span>)</div></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 7","pages":"Article 102393"},"PeriodicalIF":10.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Direct-to-Physician Marketing and Uptake of Optimal Medical Therapy for Heart Failure With Reduced Ejection Fraction","authors":"Colette DeJong MD ,&nbsp;Kosuke Inoue MD, PhD ,&nbsp;Matthew S. Durstenfeld MD, MAS ,&nbsp;Anubha Agarwal MD, MSc ,&nbsp;Justin C. Chen MD, MHPE ,&nbsp;Chien-Wen Tseng MD ,&nbsp;R. Adams Dudley MD, MBA ,&nbsp;Priscilla Y. Hsue MD ,&nbsp;Dhruv S. Kazi MD, MSc, MS","doi":"10.1016/j.jchf.2024.11.020","DOIUrl":"10.1016/j.jchf.2024.11.020","url":null,"abstract":"<div><h3>Background</h3><div>Guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction remains underused. The role of direct-to-physician marketing in accelerating uptake of GDMT is unknown.</div></div><div><h3>Objectives</h3><div>The authors investigated the association between industry marketing meals and GDMT prescribing rates under Medicare Part D.</div></div><div><h3>Methods</h3><div>The authors linked Medicare data sets to identify general and advanced heart failure (AHF) cardiologists’ prescriptions for angiotensin receptor-neprilysin inhibitors (ARNIs), sodium-glucose cotransporter 2 inhibitors (SGLT2is), angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists (MRAs), and beta-blockers from 2019 to 2021. Using negative binomial regression analyses, they examined the association between marketing meals and prescribing rates of marketed and un-marketed classes of GDMT.</div></div><div><h3>Results</h3><div>Of 11,277 general and 329 AHF cardiologists, 60% received marketing payments for ARNI and 50% for SGLT2i from 2019 to 2021. Among general cardiologists, but not AHF cardiologists, exposure to ARNI marketing meals in 2020 was associated with a greater prescribing volume of ARNI in 2021 (1-4 ARNI meals; relative ratio: 1.43 [95% CI: 1.34-1.53]; 5-9 ARNI meals; relative ratio: 1.69 [95% CI: 1.48-1.93]; ≥10 ARNI meals; relative ratio: 2.09 [95% CI: 1.80-2.43]). Findings were similar for SGLT2i. The association between marketing and prescribing of other pillars of GDMT was inconsistent across drug classes. Neither ARNI nor SGLT2i marketing was consistently associated with increased prescribing of MRAs.</div></div><div><h3>Conclusions</h3><div>Industry marketing to general cardiologists is associated with increased uptake of ARNIs and SGLT2is, but not with increased uptake of all pillars of GDMT. Improvements in comprehensive therapy for heart failure will require other mechanisms to accelerate uptake of MRAs and beta-blockers, as well as ARNIs and SGLT2is once multiple generic formulations become available in the United States.</div></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 7","pages":"Article 102380"},"PeriodicalIF":10.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GDF-15 in Cardiovascular Disease","authors":"Angelo Di Vincenzo MD,&nbsp;Federico Capone PhD,&nbsp;Marco Rossato PhD","doi":"10.1016/j.jchf.2025.03.034","DOIUrl":"10.1016/j.jchf.2025.03.034","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 7","pages":"Article 102488"},"PeriodicalIF":10.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}